Pluristem Receives Russian Patent For Placenta-Derived Cell Treatment For Inflammatory Bowel Disease

Pluristem Receives Russian Patent For Placenta-Derived Cell Treatment For Inflammatory Bowel Disease
Inflammatory Bowel DiseaseThe Israeli-based placenta cell therapies developer Pluristem Therapeutics was recently granted a patent for its study "Methods of Treating Inflammatory Colon Diseases" by Russia's Federal Service for Intellectual Property, as announced by the company. The patent covers the use of placenta-derived cells in the treatment of ulcerative colitis or Crohn's disease. For that, the company developed a protein delivery platform that releases a mixture of therapeutic proteins to combat a host of local and systemic inflammatory and ischemic conditions. "Pre-clinical studies have demonstrated that PLX cells are potentially effective in treating inflammatory bowel disease, and we may consider advancing into clinical trials with this indication in future," stated Pluristem CEO Zami Aberman. PLX cells grow trough a 3D micro-environmental technology, also a technology from Pluristem Therapeutics, which secrete therapeutic proteins in response to signals produced by damaged tissues. The product do not need tissue match prior to the administration. "This patent issued in Russia is the latest in a series of patents we've been granted across the globe for the use of placenta-derived cell therapies in a variety of different indications," the CEO added. The same patent has also been issued to Pluristem in South Africa and the company has pending requests in several other jurisdictions. Last week, the company also announced that it had received a Patent from the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *